Brent Saunders, president, CEO, and chairman of global leader Allergan, sits down at OIS@AAO to discuss what impact the pending loss of the Restasis patent could have on the company. He also rejects talk of Allergan breaking off its ophthalmology business, saying the company is in the sector to stay.